Objective: To assess the efficacy and safety of ABBV-3373, a novel antibody-drug conjugate (ADC) composed of the anti-tumor necrosis factor (anti-TNF) monoclonal antibody adalimumab linked to a glucocorticoid receptor modulator (GRM), compared to adalimumab, in patients with rheumatoid arthritis (RA).

2024年3月20日 · We have developed an anti–TNF-GRM ADC that demonstrates potent inhibitory activity both in vitro and in vivo. ABBV-3373 combines at least two specific mechanisms of anti-inflammatory activity. Because the ADC antibody scaffold consists of adalimumab, its binding and neutralization of sTNF is identical .

2022年11月17日 · In a chronic mouse arthritis model, mouse anti-TNF GRM ADCs were efficacious after a single dose of 10 mg/kg i.p. for over 30 days. Data on the unconjugated payloads and mouse surrogate anti-TNF ADCs identified payload 17 which was conjugated to a human anti-TNF antibody and advanced to the clinic as ABBV-3373.

Aims: ABBV-3373, an immunology antibody-drug conjugate composed of adalimumab conjugated to a proprietary glucocorticoid receptor modulator (the small-molecule payload), has the potential to treat immune-mediated inflammatory diseases. This first-in-human study investigated the pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) using ...

2020年6月11日 · ABBV-3373是由艾伯维开发的一种研究性ADC，由一种新型的糖皮质激素受体调节剂（GRM）连接到阿达木单抗（adalimumab），目的是通过将糖皮质激素有效载荷直接传递到表达膜结合型 肿瘤 坏死因子（TNF）的活化免疫细胞中，来调节TNF介导的炎症途径。 这种ADC被设计成可以精确地靶向活化的免疫细胞，同时显著抑制炎症和减少与糖皮质激素相关的系统性副作用。 ABBV-3373是一种未经监管机构批准的研究药物，目前正在研究用于治疗类风湿 …

2022年12月13日 · To assess the efficacy and safety of ABBV-3373, a novel antibody–drug conjugate (ADC) composed of the anti–tumor necrosis factor (anti-TNF) monoclonal antibody adalimumab linked to a glucocorticoid receptor modulator (GRM), compared to adalimumab, in patients with rheumatoid arthritis (RA).

2024年3月5日 · A scalable process to produce glucocorticoid-bearing drug-linker 1, utilized in the conjugation with the monoclonal antibody (mAb) adalimumab, has been developed. The route improves upon the first-generation approach through a …

Aims ABBV‐3373, an immunology antibody–drug conjugate composed of adalimumab conjugated to a proprietary glucocorticoid receptor modulator (the small‐molecule payload), has the potential to treat immune‐mediated inflammatory diseases.

2020年6月10日 · Being developed by AbbVie, ABBV-3373 is an investigational ADC comprised of a novel glucocorticoid receptor modulator (GRM) linked to adalimumab, and aims at modulating TNF-mediated inflammatory pathways by delivering a glucocorticoid payload directly into activated immune cells expressing membrane bound TNF.

2024年3月20日 · Clinical data for a human anti-TNF-GRM ADC (ABBV-3373) from a single ascending dose phase 1 study in healthy volunteers demonstrated antibody-like pharmacokinetic profiles and a lack of impact on serum cortisol concentrations at predicted therapeutic doses.